Structure Therapeutics (NASDAQ: GPCR) reports 2026 shareholder voting outcomes

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Structure Therapeutics Inc. held its 2026 Annual General Meeting of Shareholders on June 17, 2026. As of the April 20, 2026 record date, 213,213,565 ordinary shares were outstanding and entitled to vote. Shareholders elected Ted W. Love, M.D., Raymond Stevens, Ph.D., and Daniel G. Welch as Class III directors, each to serve until the 2029 annual meeting.

Shareholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. In an advisory vote, shareholders approved the compensation of the company’s named executive officers as described in the proxy statement for the meeting.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares entitled to vote: 213,213,565 ordinary shares Votes for Ted W. Love, M.D.: 164,241,780 votes Votes for Raymond Stevens, Ph.D.: 164,373,741 votes +3 more

6 metrics

Shares entitled to vote 213,213,565 ordinary shares Outstanding and entitled to vote as of April 20, 2026 record date

Votes for Ted W. Love, M.D. 164,241,780 votes Election as Class III director at 2026 Annual General Meeting

Votes for Raymond Stevens, Ph.D. 164,373,741 votes Election as Class III director at 2026 Annual General Meeting

Votes for Daniel G. Welch 161,336,058 votes Election as Class III director at 2026 Annual General Meeting

Auditor ratification votes for 164,767,215 votes Ratification of Ernst & Young LLP as 2026 independent auditor

Say-on-pay votes for 158,547,441 votes Advisory approval of named executive officer compensation

Key Terms

Annual General Meeting, Class III directors, independent registered public accounting firm, advisory vote, +1 more

5 terms

Annual General Meeting financial

"held its 2026 Annual General Meeting of Shareholders (the “Annual General Meeting”)"

Class III directors financial

"were elected as a Class III directors, to hold office until the 2029 Annual General Meeting"

Class III directors are members of a company’s board assigned to one of several staggered term groups, so only that class faces election in a particular year while other classes stay in place. For investors this affects corporate control and takeover risk because staggered elections make it slower and harder for an outside group to replace a majority of directors quickly—think of it as a rotating schedule for board seats that provides continuity but can also entrench existing leadership.

independent registered public accounting firm financial

"Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

advisory vote financial

"Proposal 3: Advisory vote on the compensation of the Company’s named executive officers"

An advisory vote is a shareholder poll that expresses investors’ approval or concern about a company’s policy, executive pay, board decisions or other governance matters but does not legally force the company to act. Think of it like a customer survey: it signals investor sentiment and can pressure management to change course, so investors watch the result as a guide to future governance, risk and potential shifts in strategy.

broker non-votes financial

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

06/18/2026 - 04:05 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) 

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 17, 2026

Structure Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Cayman Islands		001-41608		98-1480821
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

601 Gateway Blvd., Suite 900

South San Francisco, California

94080

(Address of principal executive offices)

(Zip Code)

(Registrant’s telephone number, including area code): (650) 457-1978

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Name Of Each Exchange Trading Symbol(s)	On Which Registered
American Depositary Shares (ADSs), each representing three ordinary shares, par value $0.0001 per ordinary share	GPCR	Nasdaq Global Market

Ordinary shares, par value $0.0001 per share*	True	Nasdaq Global Market*

* Not for trading, but only in connection with the registration of the American Depositary Shares

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 17, 2026, Structure Therapeutics Inc. (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “Annual General Meeting”). As of April 20, 2026, the record date for the Annual General Meeting, 213,213,565 ordinary shares were outstanding and entitled to vote at the Annual General Meeting. A summary of the matters voted upon by shareholders at the Annual General Meeting is set forth below.

Proposal 1: Election of Directors

Ted W. Love M.D., Raymond Stevens, Ph.D. and Daniel G. Welch were elected as a Class III directors, to hold office until the 2029 Annual General Meeting of Shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows:

Name of Director Elected	Votes For		Votes Against		Abstentions		Broker Non-Votes
Ted W. Love, M.D.		164,241,780		533,358		172,641		-0-
Raymond Stevens, Ph.D.		164,373,741		400,929		173,109		-0-
Daniel G. Welch		161,336,058		3,429,342		182,379		-0-

Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm

The Company’s shareholders ratified the appointment by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:

Votes For				Votes Against				Abstentions				Broker Non-Votes
	164,767,215				20,784				159,780				-0-

Proposal 3: Advisory vote on the compensation of the Company’s named executive officers

On an advisory basis, the shareholders approved the compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement for the Annual General Meeting. The voting results are as follows:

Votes For				Votes Against				Abstentions				Broker Non-Votes
	158,547,441				6,187,647				212,691				-0-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Structure Therapeutics Inc.

Date: June 18, 2026	By:	/s/ Matthew Lang
		Matthew Lang
		Chief Operating Officer and General Counsel

Source: View Original Filing on SEC EDGAR

FAQ

What did Structure Therapeutics (GPCR) shareholders vote on at the 2026 meeting?

Shareholders voted on three items: electing three Class III directors, ratifying Ernst & Young LLP as independent auditor for 2026, and an advisory approval of named executive officer compensation.

Who was elected to the Structure Therapeutics (GPCR) board in 2026?

Shareholders elected Ted W. Love, M.D., Raymond Stevens, Ph.D., and Daniel G. Welch as Class III directors, each to serve until the 2029 annual general meeting or earlier departure under standard corporate provisions.

How many Structure Therapeutics (GPCR) shares were eligible to vote?

As of the April 20, 2026 record date, 213,213,565 ordinary shares were outstanding and entitled to vote at the 2026 Annual General Meeting, forming the basis for all voting results disclosed.

Was Ernst & Young reappointed as Structure Therapeutics (GPCR) auditor?

Yes. Shareholders ratified the appointment of Ernst & Young LLP as Structure Therapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2026, based on the voting results reported.

Did Structure Therapeutics (GPCR) shareholders approve executive compensation?

Yes. In an advisory vote, shareholders approved the compensation of the company’s named executive officers, as described in the proxy statement for the 2026 Annual General Meeting, with votes recorded for, against, and abstaining.

What were the vote totals for Structure Therapeutics (GPCR) say-on-pay proposal?

The advisory vote on executive compensation received 158,547,441 votes for, 6,187,647 votes against, and 212,691 abstentions, with no broker non-votes reported for this proposal in the meeting results.

Filing Exhibits & Attachments

4 documents